Page 1 of 1

Oral Teriflunomide significantly reduced MS relapse rates

Posted: Mon Aug 30, 2010 12:31 am
by MSUK
Image

Sanofi-aventis announced today that the investigational once-daily oral drug teriflunomide significantly reduced annualized relapse rate (ARR) at 2 years versus placebo in patients with relapsing multiple sclerosis (RMS), thus achieving the primary endpoint in the TEMSO phase III trial.

Both the 7mg and 14mg doses of teriflunomide were well tolerated with a similar number of patients reporting either treatment-emergent adverse events (TEAEs) or TEAEs leading to treatment discontinuation in the treatment arms versus placebo.. ... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/2933